Nasdaq · Healthcare
BIODESIX INC (BDSX)
As-reported financials and recent SEC filings for BIODESIX INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$88.5M
Net income
$-35.3M
Net margin
-39.8%
Diluted EPS
$-4.67
ROE
1430.6%
P/E (TTM)
—
Market cap
—
Debt / equity
-20.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $88.5M | $71.3M | $49.1M | $38.2M | $54.5M |
| Gross profit | — | — | — | — | — |
| Operating income | $-27.9M | $-34.5M | $-41.3M | $-50.6M | $-40.9M |
| Net income | $-35.3M | $-42.9M | $-52.1M | $-65.4M | $-43.2M |
| Diluted EPS | $-4.67 | $-6.64 | $-8.32 | $-10.07 | $-10.27 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →SCHEDULE 13G2026-06-18
View on EDGAR →424B32026-06-01
View on EDGAR →EFFECT2026-05-29
View on EDGAR →S-32026-05-21
View on EDGAR →8-K2026-05-20
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →SCHEDULE 13G/A2026-05-08
View on EDGAR →Largest Healthcare peers
Go deeper on BDSX
Search BIODESIX INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.